MeiraGTx vs Twist Bioscience
MGTX and TWST side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How MGTX and TWST compare
Twist Bioscience is the larger company, worth 11 times as much as MeiraGTx ($9.6B against $911M).
MeiraGTx grew revenue faster over the last twelve months (948% versus 19.2% for Twist Bioscience).
MeiraGTx keeps more of each dollar of sales as profit, with a net margin of 19.9% compared with −31.7% at Twist Bioscience.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | MGTX | TWST |
|---|---|---|
| Size and price | ||
| Market cap | $911M | $9.6B |
| Share price | $9.49 | $152.78 |
| Change, 1 year | 6.3% | 374% |
| Change, 5 years | −54.1% | 12.4% |
| Beta (5Y) | 1.58 | 2.28 |
| Employees | 403 | 979 |
| StockData Score | ||
| Total score | 13 | 13 |
| Valuation score | 4 (better) | 0 |
| Growth score | 2 | 4 (better) |
| Performance score | 4 (better) | 3 |
| Health score | 3 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 13.4× | – |
| P/S | 2.3× (better) | 22.2× |
| P/B | – | 21.5× |
| EV/EBITDA | 4.4× | – |
| P/FCF | 87.1× | – |
| FCF yield | 1.1% (better) | −0.97% |
| Fair value | $24.09 | $34.30 |
| Margin of safety | 60.6% (better) | −345% |
| Growth | ||
| Revenue growth (TTM) | 948% (better) | 19.2% |
| Revenue growth, 5Y average | 39.2% (better) | 33.1% |
| Profitability | ||
| Gross margin | – | 52.0% |
| Operating margin | 46.3% (better) | −33.6% |
| Net margin | 19.9% (better) | −31.7% |
| FCF margin | 2.6% (better) | −21.6% |
| Return on equity | 2668% (better) | −29.6% |
| Return on invested capital | 344% (better) | −45.5% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Net debt / EBITDA | −0.22 | – |
| Interest coverage | 14.7× | – |
| Current ratio | 3.76 (better) | 2.67 |
| Altman Z-score | 3.57 | 22.67 (better) |
| Piotroski F-score | 4 | 5 (better) |
| Dividends and buybacks | ||
| Buyback yield | −14.6% | – |
| Shareholder yield | −14.6% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 82.5% | 122% |
| Held by insiders | 35.3% | 2.3% |
| Insider net buying, 12 months | −$3.8M (better) | −$126M |
| Short interest, % of float | 9.6% | 17.3% |
Go deeper
- MGTX stock overview
- MGTX income statement
- MGTX valuation and score
- TWST stock overview
- TWST income statement
- TWST valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.